CN101559084B - 一种抗肿瘤的药物组合物及其生产方法 - Google Patents
一种抗肿瘤的药物组合物及其生产方法 Download PDFInfo
- Publication number
- CN101559084B CN101559084B CN2009100979336A CN200910097933A CN101559084B CN 101559084 B CN101559084 B CN 101559084B CN 2009100979336 A CN2009100979336 A CN 2009100979336A CN 200910097933 A CN200910097933 A CN 200910097933A CN 101559084 B CN101559084 B CN 101559084B
- Authority
- CN
- China
- Prior art keywords
- extract
- hour
- filtering residue
- ethanol
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 16
- 239000000284 extract Substances 0.000 claims abstract description 225
- 241000222336 Ganoderma Species 0.000 claims abstract description 70
- 240000001080 Grifola frondosa Species 0.000 claims abstract description 69
- 235000007710 Grifola frondosa Nutrition 0.000 claims abstract description 69
- 239000003814 drug Substances 0.000 claims abstract description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 182
- 238000001914 filtration Methods 0.000 claims description 136
- 241001486992 Taiwanofungus camphoratus Species 0.000 claims description 91
- 239000000843 powder Substances 0.000 claims description 69
- 239000000706 filtrate Substances 0.000 claims description 50
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 45
- 238000001694 spray drying Methods 0.000 claims description 39
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 35
- 238000010992 reflux Methods 0.000 claims description 22
- 239000007921 spray Substances 0.000 claims description 21
- 238000001704 evaporation Methods 0.000 claims description 20
- 230000008020 evaporation Effects 0.000 claims description 20
- 239000002244 precipitate Substances 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 238000009833 condensation Methods 0.000 claims description 14
- 230000005494 condensation Effects 0.000 claims description 14
- 235000013305 food Nutrition 0.000 claims description 13
- 239000000796 flavoring agent Substances 0.000 claims description 12
- 235000019634 flavors Nutrition 0.000 claims description 12
- 238000003825 pressing Methods 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 6
- 239000010409 thin film Substances 0.000 claims description 6
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 12
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 abstract description 7
- 229960004397 cyclophosphamide Drugs 0.000 abstract description 7
- 231100000331 toxic Toxicity 0.000 abstract description 7
- 230000002588 toxic effect Effects 0.000 abstract description 7
- 241000723347 Cinnamomum Species 0.000 abstract description 4
- 230000001093 anti-cancer Effects 0.000 abstract description 4
- 238000013461 design Methods 0.000 abstract description 3
- 229930014626 natural product Natural products 0.000 abstract description 2
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- 241000386927 Cinnamomum micranthum f. kanehirae Species 0.000 abstract 2
- 229960000074 biopharmaceutical Drugs 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000000091 immunopotentiator Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000003014 reinforcing effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000233866 Fungi Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- -1 triterpenoid compound Chemical class 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- 240000003211 Corylus maxima Species 0.000 description 1
- 206010049119 Emotional distress Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 208000001907 Mushroom Poisoning Diseases 0.000 description 1
- KTHDTJVBEPMMGL-VKHMYHEASA-N N-acetyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(C)=O KTHDTJVBEPMMGL-VKHMYHEASA-N 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 241000222383 Polyporales Species 0.000 description 1
- 241000222640 Polyporus Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940108605 cyclophosphamide injection Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000010979 ruby Substances 0.000 description 1
- 229910001750 ruby Inorganic materials 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229950001390 sudismase Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000008359 toxicosis Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100979336A CN101559084B (zh) | 2009-04-23 | 2009-04-23 | 一种抗肿瘤的药物组合物及其生产方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100979336A CN101559084B (zh) | 2009-04-23 | 2009-04-23 | 一种抗肿瘤的药物组合物及其生产方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101559084A CN101559084A (zh) | 2009-10-21 |
CN101559084B true CN101559084B (zh) | 2011-06-15 |
Family
ID=41218175
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009100979336A Active CN101559084B (zh) | 2009-04-23 | 2009-04-23 | 一种抗肿瘤的药物组合物及其生产方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101559084B (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103169737B (zh) * | 2013-03-19 | 2015-02-18 | 佛山市顺德区今日景艺生物科技有限公司 | 樟芝子实体与破壁灵芝孢子粉的组合物及其在免疫调节中的应用 |
CN104116762A (zh) * | 2013-04-25 | 2014-10-29 | 中一师生物科技股份有限公司 | 牛樟芝复合配方及包含该牛樟芝复合配方的医药组成物 |
WO2016049811A1 (zh) * | 2014-09-29 | 2016-04-07 | 深圳市仁泰生物科技有限公司 | 一种富含三萜的抗肿瘤组合物及其制备方法 |
CN104306410B (zh) * | 2014-09-29 | 2019-01-08 | 深圳市仁泰生物科技有限公司 | 一种富含三萜的抗肿瘤组合物及其制备方法 |
CN104491466A (zh) * | 2014-11-28 | 2015-04-08 | 柳州市天姿园艺有限公司 | 一种含有山茱萸的牛樟芝药物组合物胶囊 |
CN104799285B (zh) * | 2015-04-29 | 2017-06-13 | 福建省中医药研究院 | 一种复方牛樟芝片剂及其制备方法 |
CN105125665A (zh) * | 2015-10-11 | 2015-12-09 | 南京市栖霞区回春堂电子商务咨询中心 | 一种含灰树花的植物组合物提取方法和应用 |
TW201728336A (zh) * | 2016-02-05 | 2017-08-16 | 台灣原生藥用植物股份有限公司 | 用以抑制腎癌細胞增生與改善腎功能之靈樟芝組合物 |
TW201740966A (zh) * | 2016-05-20 | 2017-12-01 | 台灣原生藥用植物股份有限公司 | 真菌萃取物於製備輔助治療癌症的醫藥組合物之用途 |
TWI601535B (zh) * | 2016-06-23 | 2017-10-11 | 台灣利得生物科技股份有限公司 | 牛樟段木栽培牛樟芝子實體及固態培養菌絲體水及乙醇萃取物之組合物應用於抗癌藥輔助劑 |
CN107569672A (zh) * | 2016-07-05 | 2018-01-12 | 陈栋梁 | 一种含有牛樟芝肽的抗肿瘤组合物及其制备方法及应用 |
CN107397860A (zh) * | 2017-09-02 | 2017-11-28 | 深圳市善衍生物工程有限公司 | 一种抗肿瘤生物中药制剂及加工工艺 |
CN113826737A (zh) * | 2021-08-31 | 2021-12-24 | 成都营养屋健康科技有限公司 | 一种免疫护肝茶及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1820763A (zh) * | 2005-12-19 | 2006-08-23 | 余内逊 | 一种微米灰树三花灵芝孢抗肿瘤突变颗粒、胶囊与片剂制备方法 |
CN1957956A (zh) * | 2005-10-14 | 2007-05-09 | 德阳创新生物工程有限公司 | 一种具抗肿瘤和免疫调节作用的多菌组合物及其制备方法与用途 |
CN101045899A (zh) * | 2007-05-08 | 2007-10-03 | 朴相允 | 一种有机锗Ge-132灵芝酒及制备方法 |
CN101214238A (zh) * | 2007-01-05 | 2008-07-09 | 国鼎生物科技股份有限公司 | 牛樟芝萃取物对抑制肿瘤细胞生长的应用 |
-
2009
- 2009-04-23 CN CN2009100979336A patent/CN101559084B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1957956A (zh) * | 2005-10-14 | 2007-05-09 | 德阳创新生物工程有限公司 | 一种具抗肿瘤和免疫调节作用的多菌组合物及其制备方法与用途 |
CN1820763A (zh) * | 2005-12-19 | 2006-08-23 | 余内逊 | 一种微米灰树三花灵芝孢抗肿瘤突变颗粒、胶囊与片剂制备方法 |
CN101214238A (zh) * | 2007-01-05 | 2008-07-09 | 国鼎生物科技股份有限公司 | 牛樟芝萃取物对抑制肿瘤细胞生长的应用 |
CN101045899A (zh) * | 2007-05-08 | 2007-10-03 | 朴相允 | 一种有机锗Ge-132灵芝酒及制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101559084A (zh) | 2009-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101559084B (zh) | 一种抗肿瘤的药物组合物及其生产方法 | |
CN102093598B (zh) | 一种复合食用菌多糖及其制备方法 | |
CN103860580B (zh) | 一种具有扶正固本、健脾和胃、增强免疫力功能的复合真菌多糖制剂 | |
WO2001051070A1 (fr) | Substance eem-s physiologiquement active issue de champignons, methode de production de ladite substance et medicaments | |
CN100486596C (zh) | 具有增强机体免疫力作用的中药制剂 | |
CN101249259B (zh) | 一种高含量、高活性口服云芝糖肽及其制备方法和应用 | |
CN101380346B (zh) | 一种***的中药组合物及其制作方法 | |
WO2018166151A1 (zh) | 一种用于***的中药组合物及其制备方法和用途 | |
CN102551058A (zh) | 一种具有增强免疫力功能的中药保健品 | |
CN110651941A (zh) | 蛹虫草山药固体饮料及其生产装置 | |
CN105796861A (zh) | 连翘苷、连翘苷衍生物、连翘苷与连翘脂素组合物在制备提高免疫功能的药物中的应用 | |
CN105664140A (zh) | 一种糖肽组合物及其制备方法和用途 | |
CN110973632A (zh) | 一种进行癌症膳食干预的膳食组合物及其制备方法 | |
CN105796587B (zh) | 竹茹多糖在免疫调节、抗肿瘤中的应用 | |
JPWO2005077395A1 (ja) | 生理活性組成物及びその製造方法 | |
CN106581166A (zh) | 一种具有抗疲劳功效的食品、保健品或药物组合物 | |
CN1105594A (zh) | 降癌灵丹 | |
CN104666842A (zh) | 一种参芪猴菇保健品及其制备方法 | |
TWI646964B (zh) | 用於降低癌症治療藥物副作用之醫藥組合物、製備方法及其用途 | |
WO2010076920A1 (ko) | 상황버섯과 동충하초를 포함하는 항암용 건강식품 | |
CN104739896A (zh) | 一种具有保肝功能的复合菌物胞内多糖组合物及制备方法 | |
CN108186801A (zh) | 一种香菇多糖保健口服液及其制备方法 | |
Amin et al. | Anti-obesity effect of mushroom (Ganoderma lucidum) on experimentally induced obese rats | |
CN108586626A (zh) | 一种三叶青低聚糖的制备方法及其应用 | |
CN107893035A (zh) | 一种猴头菌的培养基、黄精生物转化菌丝体、黄精生物转化菌丝体的提取物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ZHEJIANG FANGGE PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: XU CAIQUAN Effective date: 20111109 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20111109 Address after: 323800 Zhejiang province Qingyuan County Star Road Garden Bridge No. 98 Patentee after: Zhejiang Fangge Pharmaceutical Co., Ltd. Address before: 323800 Zhejiang province Qingyuan County Star Road Garden Bridge No. 98 Patentee before: Xu Caiquan |